What is Supernus Pharmaceuticals's revenue?

Supernus Pharmaceuticals (SUPN) generated $776.8M in revenue over the trailing twelve months, up 16.3% year over year.

Is Supernus Pharmaceuticals profitable?

Supernus Pharmaceuticals is not currently profitable: it reported a net loss of $29.0M over the trailing twelve months, a -3.7% net margin.

What are Supernus Pharmaceuticals's profit margins?

Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.

What is Supernus Pharmaceuticals's earnings per share?

Supernus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.51.

Where does Supernus Pharmaceuticals's income statement data come from?

Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Supernus Pharmaceuticals SUPN Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$776.83M+16.3%	$718.95M+8.6%	$681.54M+4.5%	$665.13M+5.5%	$668M+11.8%
Total cost of revenue	$82.19M+6.2%	$74.56M-4.3%	$77.65M+8.7%	$76.27M+3.8%	$77.36M+1.0%
Gross profit	$694.64M+17.6%	$644.39M+10.4%	$603.89M+4.0%	$588.85M+5.8%	$590.64M+13.4%
Gross margin	89.4%+1.0pp	89.6%+1.4pp	88.6%-0.4pp	88.5%+0.2pp	88.4%+1.2pp
Research and development	$118.75M+7.2%	$106.24M-2.4%	$107.06M+3.4%	$106.73M+9.9%	$110.79M+16.2%
Selling, general and administrative	$520.79M+60.2%	$485.56M+51.0%	$442.58M+36.8%	$332.66M-1.1%	$325.01M-3.6%
Compensation and benefits	——	——	——	——	——
Advertising	——	——	——	——	——
Depreciation and amortization	$95.8M+22.5%	$90.05M+15.5%	$83.77M+3.7%	$78.93M-4.4%	$78.22M-5.2%
Impairment charges	——	$0—	$0-100%	$0—	$0—
Total costs & expenses	$837.19M+41.1%	$781.24M+34.7%	$718.48M+21.2%	$600.99M-0.4%	$593.43M-2.9%
Operating income	-$60.36M-181%	-$62.28M-176%	-$36.94M-162%	$64.14M+141%	$74.56M+648%
Operating margin	-7.8%-18.9pp	-8.7%-21.0pp	-5.4%-14.5pp	9.6%+5.4pp	11.2%+13.4pp
Other income (expense), net	$11.21M-35.0%	$13.25M-18.2%	$16.21M+22.7%	$18.03M+65.9%	$17.23M+127%
Net investment gains (losses)	——	——	——	——	——
Income before income taxes	-$49.15M-154%	-$49.03M-150%	-$20.73M-129%	$82.16M+120%	$91.8M+1,629%
Income tax expense	——	——	-$1.62M—	$17.67M—	$29.88M—
Net income	-$29.02M-147%	-$38.55M-152%	-$19.12M-132%	$64.5M+1,131%	$61.91M+499%
Net margin	-3.7%-13.0pp	-5.4%-16.5pp	-2.8%-12.0pp	9.7%+8.9pp	9.3%+11.9pp
Diluted earnings per share	-$0.51-146%	-$0.68-152%	-$0.34-132%	$1.15+1,178%	$1.11+483%
Basic earnings per share	-$0.51-145%	-$0.68-151%	-$0.33-131%	$1.17+1,200%	$1.13+490%
Weighted-average shares, diluted	227.3M+1.7%	225.5M+1.0%	225M+1.0%	224.5M+1.4%	223.6M+1.5%
Weighted-average shares, basic	226.7M+2.5%	224.9M+2.2%	223.5M+1.9%	222.1M+1.5%	221.1M+1.2%
Share-based compensation expense related to employee stock plans	——	——	——	——	——
Advertising costs	——	——	——	——	——
Pre-tax stock-based compensation cost	——	——	——	——	——
Amortization of capitalized software and acquired intangible assets	$95.31M+22.8%	$89.46M+14.7%	$83.17M+2.9%	$78.34M-5.1%	$77.63M-6.0%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1	$20.15M+780%	$25.42M+493%	$7.66M+215%	$6.64M+209%	$2.29M+337%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	——	——	——
Prior year sale adjustments, percentage	——	——	——	——	——
Credit losses on securities without previous credit losses	$0—	$0—	——	——	——
Total net securities (losses)	——	——	——	——	-$2.25K-200%
Deferred taxes	$15.11M+181%	$5.21M+126%	-$13.87M+54.6%	-$17.69M+46.9%	-$18.64M+39.4%
Effective tax rates	——	——	——	——	——
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings	——	——	——	——	——
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements	——	——	——	——	——
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification	——	——	——	——	——
Goodwill activity from Sage Acquisition	$1.68M—	$7.86M—	——	——	——
Income Taxes Paid, Net	$15.37M-71.1%	$16.05M-69.9%	$28.69M-42.5%	$45.19M+22.4%	$53.19M+44.8%
Accounts payable and other current liabilities	-$28.46M-34.9%	-$24.57M-63.6%	-$24.49M-64.8%	-$14.79M-62.1%	-$21.1M-34.2%
Increase (Decrease) in Accounts Receivable	$13.12M+727%	$22.3M+1,173%	$2.55M—	-$11.66M—	-$2.09M—
Accrued product returns and rebates	——	——	——	——	——
Increase (Decrease) in Inventories	$12.34M+167%	$7.5M+147%	$135K+101%	-$17.41M+12.8%	-$18.55M-86.4%
Increase (Decrease) in Prepaid Expense and Other Assets	$32.98M+535%	$13.18M-34.4%	$17.08M—	$7.69M—	$5.19M—
Add - Incremental shares under stock-based compensation plans (in shares)	——	——	——	——	——
Insurance Recoveries	——	——	——	——	——
Inventory Write Down	——	——	——	——	——
(Amortization) accretion on investments	——	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$39.64M+468%	$9.13M-25.1%	$6.49M+3.0%	-$11.5M-484%	-$10.78M+97.7%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	——	——	——	——	-$100.93M—
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	——	——	——	$187.06M+20.8%	$164.15M—
Number of commercial products	——	——	——	——	——
Number of operating segments	——	——	——	——	——
Number of reportable segments	——	——	——	——	——
Operating lease right-of-use assets amortization expense	——	——	——	——	$5.43M-13.0%
Other comprehensive income/(loss)	——	——	——	——	——
Net unrealized gains (losses) on securities still held	——	——	——	——	——
Other Noncash Income (Expense)	——	——	——	——	——
Other income, net (Note 6)	$11.21M-35.0%	$13.25M-18.2%	$16.21M+22.7%	$18.03M+65.9%	$17.23M+103%
Payment for Contingent Consideration Liability, Financing Activities	$4.16M-79.3%	$24.26M—	$24.26M—	$22.4M—	$20.1M—
Payment for Contingent Consideration Liability, Operating Activities	——	——	——	——	——
Payment, Tax Withholding, Share-Based Payment Arrangement	$5.44M+15.4%	$4.23M+55.8%	$5.19M+200%	$4.76M+106%	$4.72M+63.5%
Payments to Acquire Debt Securities, Available-for-Sale	$435.82M-28.9%	$475.94M-30.8%	$531.15M-17.6%	$629.45M+50.1%	$612.87M+108%
Payments to Acquire Property, Plant, and Equipment	$1.01M+25.7%	$1.34M+84.6%	$1.12M+120%	$1.2M+159%	$804K+44.3%
Proceeds from Issuance of Common Stock	$49.24M+251%	$37.62M+152%	$35.94M+294%	$15.66M+145%	$14.04M+93.3%
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale	$677.5M+32.1%	$774.48M+55.2%	$868.14M+116%	$547.7M+90.1%	$512.75M—
Collaboration revenue, percentage	——	——	——	——	——
Revenue From Contract With Customer Excluding Assessed Tax	$776.83M+16.3%	$718.95M+8.6%	$681.54M+4.5%	$665.13M+5.5%	$668M+11.8%
Stock-based compensation	$33.46M+11.8%	$33.05M+19.1%	$31.03M+16.8%	$30.88M+15.2%	$29.93M+13.6%
Granted (in shares)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	——	——	——	——	——
Options canceled (in dollars per share)	——	——	——	——	——
Granted (in shares)	——	——	——	——	——
Exercised (in shares)	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	——	——	——	——	——
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	——	——	——	——	——
EBIT	-$60.36M-181%	-$62.28M-176%	-$36.94M-162%	$64.14M+141%	$74.56M+648%
EBITDA	$36.95M-76.1%	$29.28M-81.9%	$48.45M-66.0%	$144.82M+29.8%	$154.61M+117%
EBITDA	$36.95M-76.1%	$29.28M-81.9%	$48.45M-66.0%	$144.82M+29.8%	$154.61M+117%
EBITDA margin	4.8%-18.4pp	4.1%-20.4pp	7.1%-14.7pp	21.8%+4.1pp	23.1%+11.2pp
EBIT	-$60.36M-181%	-$62.28M-176%	-$36.94M-162%	$64.14M+141%	$74.56M+648%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Supernus Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's revenue?: Supernus Pharmaceuticals (SUPN) generated $776.8M in revenue over the trailing twelve months, up 16.3% year over year.
Is Supernus Pharmaceuticals profitable?: Supernus Pharmaceuticals is not currently profitable: it reported a net loss of $29.0M over the trailing twelve months, a -3.7% net margin.
What are Supernus Pharmaceuticals's profit margins?: Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.
What is Supernus Pharmaceuticals's earnings per share?: Supernus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.51.
Where does Supernus Pharmaceuticals's income statement data come from?: Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.